Bremner J D, Wingard P, Walshe T A
Bremner Research Institute, University of Washington School of Medicine, Olympia 98502, USA.
J Clin Psychiatry. 1998 May;59(5):233-5. doi: 10.4088/jcp.v59n0505.
We report 6 confirmed cases of substantial overdose with mirtazapine, a new antidepressant compound, that occurred up to January 1997 in the United States during postmarketing surveillance or in the clinical trials.
In 6 patients, the mirtazapine doses ranged from 10 to 30 times the maximum recommended dose, and there were no serious adverse effects of overdose. Two patients at special risk, a 90-year-old man and a 3-year-old child, took higher-than-usual doses without serious sequelae. The 4 patients who combined other central nervous system (CNS) depressants with mirtazapine appeared to experience more CNS depression. One patient who ingested 60 mg of alprazolam had clinically significant respiratory depression in the emergency room but recovered fully within 24 hours.
After an overdose of substantial multiples of mirtazapine that exceed the maximum recommended daily dosage, the new antidepressant mirtazapine appears to be safe in a limited number of cases.
我们报告了6例米氮平严重过量的确诊病例，米氮平是一种新型抗抑郁化合物，这些病例于1997年1月前在美国上市后监测期间或临床试验中发生。
6例患者服用的米氮平剂量为最大推荐剂量的10至30倍，且过量服用未产生严重不良反应。两名具有特殊风险的患者，一名90岁男性和一名3岁儿童，服用了高于平常剂量的米氮平，未出现严重后遗症。4例将其他中枢神经系统（CNS）抑制剂与米氮平合用的患者似乎出现了更严重的CNS抑制。一名摄入60毫克阿普唑仑的患者在急诊室出现了具有临床意义的呼吸抑制，但在24小时内完全康复。
在过量服用超过最大推荐日剂量数倍的米氮平后，这种新型抗抑郁药在少数病例中似乎是安全的。
